WallStreetZenWallStreetZen

NASDAQ: APLS
Apellis Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

APLS past revenue growth

How has APLS's revenue growth performed historically?
Company
425.83%
Industry
144.63%
Market
17.55%
APLS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
APLS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
APLS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

APLS earnings and revenue history

Current Revenue
$396.6M
Current Earnings
-$528.6M
Current Profit Margin
-133.3%

APLS Return on Equity

Current Company
-178.5%
Current Industry
-63.5%
Current Market
188%
APLS's Return on Equity (-178.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when APLS announces earnings.

APLS Return on Assets

Current Company
-60.4%
Current Industry
2.9%
APLS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

APLS Return on Capital Employed

Current Company
-91.83%
Current Industry
19.5%
APLS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

APLS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
APLS$396.59M-$495.21M-$528.63M+83.50%N/A
IONS$787.65M-$230.01M-$366.29M+5.60%N/A
RVMD$11.58M-$430.28M-$436.37M-10.50%N/A
BPMC$249.38M-$466.45M-$506.98M+41.14%N/A
PCVX$0.00-$392.10M-$402.27MN/AN/A
View Top Biotech Stocks

APLS earnings dates

Next earnings date
Jun 5, 2024

Apellis Pharmaceuticals Earnings & Revenue FAQ

What were APLS's earnings last quarter?

On Invalid Date, Apellis Pharmaceuticals (NASDAQ: APLS) reported Q4 2023 earnings per share (EPS) of -$0.72, up 52% year over year. Total Apellis Pharmaceuticals earnings for the quarter were -$88.58 million. In the same quarter last year, Apellis Pharmaceuticals's earnings per share (EPS) was -$1.50.

If you're new to stock investing, here's how to buy Apellis Pharmaceuticals stock.

What was APLS's earnings growth in the past year?

As of Q2 2024, Apellis Pharmaceuticals's earnings has grown year over year. Apellis Pharmaceuticals's earnings in the past year totalled -$528.63 million.

What is APLS's earnings date?

Apellis Pharmaceuticals's earnings date is Invalid Date. Add APLS to your watchlist to be reminded of APLS's next earnings announcement.

What was APLS's revenue last quarter?

On Invalid Date, Apellis Pharmaceuticals (NASDAQ: APLS) reported Q4 2023 revenue of $146.38 million up 545.89% year over year. In the same quarter last year, Apellis Pharmaceuticals's revenue was $22.66 million.

What was APLS's revenue growth in the past year?

As of Q2 2024, Apellis Pharmaceuticals's revenue has grown 425.83% year over year. This is 281.2 percentage points higher than the US Biotechnology industry revenue growth rate of 144.63%. Apellis Pharmaceuticals's revenue in the past year totalled $396.59 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.